Related Experiment Video

Updated: Jun 17, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis

Andrea Tesija-Kuna1, Simeon Grazio, Marijana Miler

  • 1University Department of Chemistry, Sestre Milosrdnice University Hospital, Vinogradska 29, 10000, Zagreb, Croatia. andrea.kuna@gmail.com

Clinical Rheumatology
|January 14, 2010
PubMed

Insights

Antibodies against mutated citrullinated vimentin (anti-MCV) are rarely found in psoriatic arthritis (PsA) patients, unlike in rheumatoid arthritis (RA). This study found anti-MCV in only 3.6% of PsA patients, suggesting limited diagnostic utility for PsA.

Area of Science:

  • Immunology
  • Rheumatology
  • Clinical Diagnostics

Background:

  • Antibodies against mutated citrullinated vimentin (anti-MCV) and antibodies against citrullinated peptides (anti-CCP) are key biomarkers for rheumatoid arthritis (RA).
  • While anti-CCP antibodies are found in some psoriatic arthritis (PsA) patients, the prevalence and significance of anti-MCV antibodies in PsA remain largely uninvestigated.

Purpose of the Study:

  • To determine the prevalence and clinical relevance of anti-MCV antibodies in patients diagnosed with psoriatic arthritis (PsA).

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to analyze serum samples from 56 PsA patients for anti-MCV and anti-CCP antibodies.
  • Clinical data, disease activity, and functional status were recorded by a rheumatologist.
  • Prevalence data were compared with those from a previous study including RA patients, other inflammatory rheumatic diseases, and healthy controls.

Main Results:

  • Anti-MCV antibodies were detected in only 2 out of 56 (3.6%) PsA patients, a significantly lower prevalence compared to RA patients (63%).
  • The positive cases exhibited asymmetric polyarthritis, dactylitis, moderate to high disease activity, and were negative for anti-CCP and rheumatoid factor (RF).
  • No significant association was found between anti-MCV levels and PsA clinical subtypes, anti-CCP, RF, disease activity, or functional indices.

Conclusions:

  • Anti-MCV antibodies are present in a very small subset of PsA patients, primarily those with a polyarthritic presentation.
  • The findings suggest that anti-MCV antibodies are not a significant diagnostic marker for PsA and their presence may be related to polyarthritic patterns rather than a specific diagnosis of RA.

More Related Videos

Anti-Nuclear Antibody Screening Using HEp-2 Cells13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Related Concept Videos

Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...